Geoffrey J. Lindeman

Geoffrey J. Lindeman

Auto-generated profile, based on publicly available information

Geoffrey J. Lindeman

Cancer Biology and Stem Cells Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, Australia

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2008 in Nature Reviews Cancer
Verified
Journal Article
Closed access
PDF file
JVJane E. Visvader
Jane E. Visvader
GLGeoffrey J. Lindeman
Geoffrey J. Lindeman

5 January 2006 in Nature
Verified
Journal Article
Closed access
PDF file
MSMark Shackleton
Mark Shackleton
FVFrançois Vaillant
François Vaillant
KSKaylene Simpson
Kaylene Simpson
JSJohn Stingl
John Stingl
GSGordon Smyth
Gordon Smyth
JVJane E. Visvader
Jane E. Visvader

2 August 2009 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
KFk Con Fab
k Con Fab
ELElgene Lim
Elgene Lim
FVFrançois Vaillant
François Vaillant
DWDi Wu
Di Wu
NFNatasha C Forrest
Natasha C Forrest
GLGeoffrey J Lindeman
Geoffrey J Lindeman

1 June 2012 in Cell Stem Cell
Verified
Journal Article
Closed access
JVJane E. Visvader
Jane E. Visvader
GLGeoffrey J. Lindeman
Geoffrey J. Lindeman

7 August 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
AAAntonis C. Antoniou
Antonis C. Antoniou
SCSilvia Casadei
Silvia Casadei
THTuomas Heikkinen
Tuomas Heikkinen
DBDaniel Barrowdale
Daniel Barrowdale
KPKatri Pylkäs
Katri Pylkäs
MTMarc Tischkowitz
Marc Tischkowitz
To the Editor: We read the article by Antoniou et al. (August 7 issue)1 because we like to know the penetrance of breast-cancer genes before we recommend surgery. After reading the article, we are unsure of what to tell patients. The simplest message would be that the risk up to 70 years of age is 35%, but this is based on an analysis of patients who received a diagnosis of breast cancer from 1930 to the present. The relevant risk value is that for a woman without breast cancer who is found to have a PALB2 mutation today. Most patients . . .

24 December 2006 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
MAMarie-Liesse Asselin-Labat
Marie-Liesse Asselin-Labat
KSKate D. Sutherland
Kate D. Sutherland
HBHolly Barker
Holly Barker
RTRichard Thomas
Richard Thomas
MSMark Shackleton
Mark Shackleton
JVJane E. Visvader
Jane E. Visvader